Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a ...

New real-world evidence highlights lebrikizumab’s effectiveness and safety in atopic dermatitis. Discover how patients ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93 billion in 2024 and is expected to reach USD 29.43 billion by 2032, registering a compound annual growth ...

Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...